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ABSTRACT: The bottromycins belong to the ribosomally syn-
thesized and posttranslationally modified peptide (RiPP) family of 
natural products. Bottromycins exhibit unique structural features, 
including a hallmark macrolactamidine ring and thiazole heterocy-
cle for which divergent members of the YcaO superfamily have 
been biosynthetically implicated. Here we report the in vitro recon-
stitution of two YcaO proteins, BmbD and BmbE, responsible for 
the ATP-dependent cyclodehydration reactions that yield thia-
zoline- and macrolactamidine-functionalized products, respec-
tively. We also establish the substrate tolerance for BmbD and 
BmbE and systematically dissect the role of the follower peptide, 
which we show serves a purpose similar to canonical leader pep-
tides in directing the biosynthetic enzymes to the substrate. Lastly, 
we leverage the expanded capabilities of YcaO proteins to conduct 
an extensive bioinformatic survey to classify known YcaO chem-
istry. This analysis predicts new functions remain to be uncovered 
within the superfamily. 
Ribosomally synthesized and posttranslationally modified peptides 
(RiPPs) are a growing natural product class with remarkable struc-
tural diversity.1 RiPP precursor peptides are direct gene products 
that undergo various posttranslational modifications by locally en-
coded biosynthetic enzymes.2 RiPP precursor peptides are func-
tionally bipartite with the modifications typically being installed on 
the C-terminal “core peptide” region of the precursor. The N-ter-
minal “leader peptide” region frequently contains recognition se-
quences that are bound by the biosynthetic enzymes. The bottro-
mycin RiPP class possesses an unusually high density of posttrans-
lational modifications on a small (8-mer) core peptide3-6 and inverts 
the RiPP precursor paradigm by displaying an N-terminal core pep-
tide and C-terminal “follower peptide” (Figure 1). The biosyn-
thetic gene cluster for bottromycin was reported in 2012 by four 
independent groups, which demonstrated that the sequences of both 
the precursor peptide and the tailoring genes are strongly conserved 
in several Streptomyces species (Figure S1 and Table S1).7-10  
Despite considerable progress in characterizing several posttrans-
lational modifications present in bottromycin,6,8-11 the formation of 
the macrolactamidine, which involves Gly1 and Val4, as well as a 
thiazoline derived from Cys8, have remained enigmatic (Figure 1).  
 
Figure 1 (A) Organization of the bottromycin biosynthetic gene cluster in 
Streptomyces bottropensis. (B) Precursor peptide sequence and reactions 
catalyzed by the two YcaO proteins (BmbD and BmbE). (C) Structure of 
bottromycin A2. 
Deletion of three genes encoding class B radical-S-adenosylmethi-
onine (SAM) methytransferases produced bottromycin analogs 
lacking methyl groups on the -carbons of Pro2, Val3/Val4 and 
Phe6.7-9 However, two proteins belonging to the YcaO superfamily 
(BmbD and BmbE, protein family PF02624)12 lacked clearly de-
fined functions, but were hypothesized to be involved in modifica-
tions requiring activation of the peptide backbone.7,8 Work from 
our group has demonstrated that members of the YcaO superfamily 
utilize ATP to directly O-phosphorylate backbone amides resulting 
in the formation of azoline heterocycles using the nucleophilic side 
chains of Cys, Ser, and Thr residues.13,14 Individual deletion of 
 bmbE and bmbH homologs in Streptomyces scabies were capable 
of producing a species consistent with a methylated, thiazoline-
containing linear peptide, suggesting BmbE and BmbH cooperate 
to form the macrolactamidine. However, the precise roles of these 
proteins, as well as the origin of the thiazoline, has remained unre-
solved.11 
All previous in vitro characterization of the YcaO superfamily has 
focused on biosynthetic gene clusters that encode a YcaO partner 
protein from either the E1 ubiquitin-activating enzyme15,16 or ocin-
ThiF-like protein family (PF00899).14 These partner proteins are 
found either as N-terminal fusions to the YcaO or as discrete pro-
teins. Both varieties contain a ~90-residue domain known as the 
RiPP precursor peptide recognition element (RRE) that physically 
engages the peptide substrate and delivers the core region to the 
biosynthetic enzymes.17 In contrast, bottromycin gene clusters con-
tain RRE domains on the radical-SAM methyltransferases (Figure 
1) and the BmbD and BmbE proteins bear minimal sequence simi-
larity to canonical YcaOs outside of the conserved ATP-binding 
site (Figure S2).14 Intrigued by the putative involvement of RRE-
independent YcaOs in macrolactamidine and thiazoline formation, 
we sought to characterize the catalytic activity of BmbD and BmbE 
in vitro. 
 
Figure 2 MALDI-TOF-MS analysis of (A) precursor peptide BmbC calc. 
m/z 4675 (B) Reaction with BmbD yields ions with an m/z value consistent 
with dehydration. (C) BmbD reaction omitting ATP. (D) Same as panel B 
but with BmbE. (E) BmbE reaction omitting ATP. 
The bmbD and bmbE genes were cloned into an expression vector 
that affords an N-terminal fusion to maltose-binding protein (Ta-
bles S2-S3). The corresponding proteins were overproduced in 
Escherichia coli and purified by amylose affinity chromatography 
(Figure S3). The precursor peptide, BmbC, was overproduced in a 
form that lacks the N-terminal Met residue. Treatment of BmbC 
with BmbD resulted in the ATP-dependent loss of 18 Da, consistent 
with dehydration as assessed by matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry (MALDI-TOF-MS, 
Figure 2). An identical result was obtained when treating BmbC 
with BmbE. These findings are in accord with the known chemistry 
catalyzed by YcaO cyclodehydratases.2 Furthermore, the Glu-rich, 
ATP-binding motifs conserved amongst YcaOs were essential for 
BmbD and BmbE processing, as substitution with Ala abolished 
activity (Figures S2, S4). Unlike canonical E1/ocin-ThiF-depend-
ent, azoline-forming YcaOs,13 BmbD and BmbE do not contain 
Pro-rich C-termini; instead, their C-termini are relatively basic. 
Modest truncations (20) to the C-termini did not abolish activity 
for either enzyme, which stands in contrast to YcaOs with Pro-rich 
C-termini (Figure S5).  
To determine which dehydration reaction was catalyzed by which 
protein, we exploited the fact that the thiazoline product contains a 
primary amino group (Gly1), whereas the macrolactamidine prod-
uct contains a thiol group (Cys8). Thus, the products of the BmbD 
and BmbE reactions were subjected to an amine-specific reductive 
amination with formaldehyde and borane and thiol-specific alkyla-
tion with 2-bromoethylamine and subsequently analyzed by 
MALDI-TOF-MS. As expected, the thiazoline product underwent 
dimethylation on the Gly1 N-terminus while the macrolactamidine 
product was alkylated on the Cys8 side chain with no cross-prod-
ucts observed. Moreover, a BmbC-C8A variant was processed by 
BmbE, but not BmbD, which together implicated BmbD in thia-
zoline formation and BmbE in macrolactamidine formation (Fig-
ure S6, Table S4). High-resolution electrospray ionization tandem 
MS (HR-ESI-MS/MS) confirmed the locations of these posttrans-
lational modifications (Figure S7, Table S5).  
NMR spectroscopic analysis of a trypsin-treated BmbC-N15K var-
iant was performed to further characterize the BmbC starting ma-
terial and the BmbD/BmbE reaction products. 1H chemical shifts 
and the absence of characteristic nuclear Overhauser effect corre-
lations in DMSO suggested the absence of secondary structure in 
unmodified BmbC. Comparison of the spectra for BmbC before 
and after BmbD processing showed that the only significant differ-
ences were in the region around Cys8, including: the amide protons 
for Asp7, Met9, Thr10, and Ala11; the C protons for Asp7 and 
Met9; the C protons of Met9 (Figure S8). Moreover, the signals 
for the C and C protons of Cys8 were shifted to values typically 
observed for thiazoline-containing peptides (Table S6).18 The same 
analysis was performed for BmbE-treated BmbC, where the C and 
C protons for Val3-5, as well as the C, C, and C protons of 
Pro2 were strongly shifted in comparison with unmodified BmbC 
(Figure S8). More modest changes were detected for the Phe6 and 
Asp7 protons. Collectively, the chemical labeling, processing of 
BmbC-C8A, HR-ESI-MS/MS, and NMR data allow the unambig-
uous assignment of thiazoline formation to BmbD and macrolac-
tamidine formation to BmbE. 
Typical YcaO cyclodehydratases bind their substrates via an RRE-
containing partner protein;14 however, BmbD and BmbE were cat-
alytically competent in vitro in the absence of any partner protein. 
For BmbE, this finding is in contrast to a previous in vivo metabo-
lomics study that implicated BmbH in macrolactamidine for-
mation.11 To assess if BmbH or BmbG (another functionally unas-
signed protein, Figure 1) enhanced BmbE activity in vitro, the pro-
teins were individually supplied to the YcaO reaction mixture. Nei-
ther addition of BmbH or BmbG resulted in more product for-
mation. Identical results were obtained when BmbD reactions were 
supplemented with BmbG/H (Figure S9). 
  
Figure 3 Substrate tolerance of BmbD and BmbE (A) Core peptide variants 
processed by each YcaO.  indicates amino acid deletion at this position. 
(B) Activity of BmbC variants with Ala substitution in the follower peptide. 
The Phe13-Asp17 and Glu22-Glu32 regions were targeted based on their 
similarity to the lanthipeptide and cyanobactin recognition sequences, re-
spectively. Circles indicate sites of Ala substitution. Filled circles indicate 
variants that inhibited BmbD or BmbE processing. 
A previous heterologous expression study10 showed that the bottro-
mycin biosynthetic pathway was largely intolerant towards accept-
ing BmbC variants. To determine if the same was true in vitro, we 
evaluated 21 BmbC variants as BmbD/BmbE substrates using a 
MALDI-TOF-MS endpoint assay (Figures 3, S7). As observed for 
other RiPPs,19 the variants were more widely tolerated as substrates 
in vitro as opposed to in vivo (Table S4). However, BmbD was still 
only able to process Cys8 and substitution of distal residues could 
abolish thiazoline formation. Similarly, BmbE exclusively formed 
a macrolactamidine with the fourth residue of BmbC and attempts 
to alter macrocycle size were unsuccessful (Table S2).  
We next investigated if the BmbC follower peptide played a role in 
substrate recognition. Stop codons (denoted as asterisks) were in-
troduced to produce C-terminal truncations of BmbC at intervals of 
five to identify the minimal sequence compatible with 
BmbD/BmbE processing. Consistent with follower peptide se-
quence conservation (Figure S1), BmbC-G35* was processed 
while E30* was not (Figure S10). Analysis of additional trunca-
tions confirmed that residues 1-34 of BmbC represents the mini-
mum substrate for BmbD and BmbE.  
The follower peptide of BmbC contains regions that are reminis-
cent of lanthipeptide and cyanobactin recognition sequences (Fig-
ure 3).20,21 To determine the relevance of these regions, 15 residues 
were individually replaced with Ala and assessed as BmbD/BmbE 
substrates. Despite their sequence divergence and the lack of a rec-
ognizable RRE, many of the same BmbC residues were important 
for both BmbD and BmbE processing (Figures 3, S11). To directly 
measure the binding affinity towards BmbD/BmbE, we prepared 
double variant BmbC-C8S/S43C to allow for the selective installa-
tion of fluorescein near the C-terminus of the peptide (Figure S12). 
Using a fluorescence polarization assay, the dissociation constants 
(KD) for BmbD and BmbE were estimated to be greater than 50 µM 
(Figure S13). As mentioned above, the bottromycin biosynthetic 
gene cluster does indeed encode proteins with RREs, but these do-
mains are fused to the C-termini of the rSAM methyltransferases. 
To evaluate their role in BmbC binding, we excised the RRE do-
mains from BmbB and BmbF and subjected the proteins to the 
same fluorescence polarization assay. The binding affinities for 
BmbC were significantly tighter relative to the YcaOs with KD val-
ues of 876 ± 67 nM (BmbB) and 597 ± 25 nM (BmbF). Further 
studies are warranted to reconcile how these binding and activity 
data fit into the yet-unresolved order of events during bottromycin 
biosynthesis. 
Having confirmed a new activity for an RRE-independent YcaO in 
vitro, we wondered how often YcaOs are encoded in genomic con-
texts consistent with macrolactamidine and azoline formation. For 
this, we employed RODEO (Rapid ORF Description and Evalua-
tion Online)22 to catalog the co-occurrence frequency of protein 
families for the ~13,000 YcaO proteins deposited in GenBank (Fig-
ure S14). Less than one-third of all YcaOs co-occur with a E1/ocin-
ThiF-like member, which is the arrangement found in several RiPP 
classes, including linear azol(in)e-containing peptides, thiopep-
tides, and cyanobactins. A separate subset of YcaO proteins (~8% 
of the total) co-occur with “TfuA”, a protein of unknown function. 
Recent work from our group has shown that the TfuA-YcaO pair 
found in methanogenic archaea is responsible for installing a thio-
glycine moiety in methyl-coenzyme M reductase.23 This result sug-
gests that the TfuA-YcaO present in the thioviridamide biosyn-
thetic gene cluster would similarly be responsible for thioamide 
formation.24  
To shed light on the potential function of the remaining 60+% of 
YcaOs, we analyzed the local genomic region for Pfam co-occur-
rence (Table S7) as well as generated sequence similarity networks 
to assess phylogenetic and relatedness trends (Figure S15). We 
then created custom profile hidden Markov models25 based on 
known BmbD and BmbE homologs to discriminate between az-
oline- and amidine-forming YcaOs and reanalyzed the networks 
based on the resulting expectation values (Figures S16-17). While 
very few of the uncharacterized YcaOs were similar to BmbD (az-
oline-forming YcaO), one-third of the sequences showed signifi-
cant similarity to BmbE, suggesting that amidine-forming YcaOs 
may be more prevalent than currently appreciated.26 The data fur-
ther predict that RRE-independent azoline-forming YcaOs may be 
relatively rare (Figure S18).  
In summary, our work has delineated the roles of BmbD, BmbE, 
and the follower peptide in bottromycin biosynthesis.  BmbE has 
been confirmed to carry out a new enzymatic reaction for the YcaO 
superfamily. Our bioinformatic analysis not only implicates YcaO 
involvement in a diversity of new natural product biosynthetic gene 
clusters, but also a significant potential for new chemistry that 
would expand upon the established roles in azoline, thioamide, and 
amidine formation. 
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